Hanik Kholidah
- cholesterol
- first
- July 17, 2026
- 0 Comments
FDA Grants Priority Review to Lipfendra as First Oral PCSK9 Inhibitor for LDL Cholesterol Management
The U.S. Food and Drug Administration (FDA) has officially granted priority review to Lipfendra (enlicitide), a move that signals a potential paradigm shift in the management of cardiovascular health. Developed…
